Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2944757rdf:typepubmed:Citationlld:pubmed
pubmed-article:2944757lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2944757lifeskim:mentionsumls-concept:C0014563lld:lifeskim
pubmed-article:2944757lifeskim:mentionsumls-concept:C0032176lld:lifeskim
pubmed-article:2944757lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2944757lifeskim:mentionsumls-concept:C1854187lld:lifeskim
pubmed-article:2944757lifeskim:mentionsumls-concept:C0032172lld:lifeskim
pubmed-article:2944757lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:2944757lifeskim:mentionsumls-concept:C1548982lld:lifeskim
pubmed-article:2944757lifeskim:mentionsumls-concept:C0283766lld:lifeskim
pubmed-article:2944757pubmed:issue1-2lld:pubmed
pubmed-article:2944757pubmed:dateCreated1986-11-17lld:pubmed
pubmed-article:2944757pubmed:abstractTextThe effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7- ethoxycarbonylmethoxycoumarin) was studied in vitro on washed human platelet aggregation and beta-thromboglobulin (beta TG) release induced by PAF alone or in combination with epinephrine. AD6 caused concentration-dependent inhibition of aggregation and beta TG release. Acetylsalicylic acid and the ADP scavenger apyrase were ineffective on the same parameters, while the specific PAF antagonist CV 3988, the Ca2+ antagonist diltiazem and the cyclo-oxygenase-lipoxygenase inhibitors nordihydroguaiaretic acid and BW 755C inhibited aggregation. The results indicate that AD6 is an inhibitor of platelet aggregation in vitro with a mode of action different from cyclo-oxygenase blockade.lld:pubmed
pubmed-article:2944757pubmed:languageenglld:pubmed
pubmed-article:2944757pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:citationSubsetIMlld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2944757pubmed:statusMEDLINElld:pubmed
pubmed-article:2944757pubmed:monthAuglld:pubmed
pubmed-article:2944757pubmed:issn0014-2999lld:pubmed
pubmed-article:2944757pubmed:authorpubmed-author:DejanaEElld:pubmed
pubmed-article:2944757pubmed:authorpubmed-author:ProsdocimiMMlld:pubmed
pubmed-article:2944757pubmed:authorpubmed-author:ZanettiAAlld:pubmed
pubmed-article:2944757pubmed:authorpubmed-author:ZattaAAlld:pubmed
pubmed-article:2944757pubmed:issnTypePrintlld:pubmed
pubmed-article:2944757pubmed:day22lld:pubmed
pubmed-article:2944757pubmed:volume128lld:pubmed
pubmed-article:2944757pubmed:ownerNLMlld:pubmed
pubmed-article:2944757pubmed:authorsCompleteYlld:pubmed
pubmed-article:2944757pubmed:pagination119-27lld:pubmed
pubmed-article:2944757pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:meshHeadingpubmed-meshheading:2944757-...lld:pubmed
pubmed-article:2944757pubmed:year1986lld:pubmed
pubmed-article:2944757pubmed:articleTitleThe effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxy- carbonylmethoxycoumarin) on washed human platelet aggregation induced by platelet activating factor (PAF) and epinephrine.lld:pubmed
pubmed-article:2944757pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2944757pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2944757pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:2944757pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed